These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Oberdhan D; Cole JC; Krasa HB; Cheng R; Czerwiec FS; Hays RD; Chapman AB; Perrone RD Am J Kidney Dis; 2018 Feb; 71(2):225-235. PubMed ID: 29150246 [TBL] [Abstract][Full Text] [Related]
13. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study. Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027 [TBL] [Abstract][Full Text] [Related]
14. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. Xue C; Zhou CC; Wu M; Mei CL Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038 [TBL] [Abstract][Full Text] [Related]
15. Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership. Harris T; Bridges HR; Brown WD; O'Brien NL; Daly AC; Jindal BK; Mundy GS; Ong A; Power AJ; Sandford RN; Sayer J; Simms RJ; Wilson PD; Winyard PJD; Tarpey M BMJ Open; 2022 Jun; 12(6):e055780. PubMed ID: 35705349 [TBL] [Abstract][Full Text] [Related]
17. Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study. Chasan O; Mirioglu S; Artan AS; Gursu M; Kazancioglu R; Elcioglu OC Clin Exp Nephrol; 2023 Nov; 27(11):912-918. PubMed ID: 37493903 [TBL] [Abstract][Full Text] [Related]
18. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US. Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357 [TBL] [Abstract][Full Text] [Related]
19. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial. Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092 [TBL] [Abstract][Full Text] [Related]
20. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]